Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573 in Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Dec 2017
At a glance
- Drugs HM 95573 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Hanmi Pharmaceutical
- 05 Feb 2017 Planned End Date changed from 31 Dec 2016 to 1 Sep 2017.
- 05 Feb 2017 Planned primary completion date changed from 31 Dec 2016 to 1 Sep 2017.
- 05 Feb 2017 Status changed from recruiting to active, no longer recruiting.